

## Draft programme of work

Date and time	Item
<p><b>19–21 October</b></p> <p><b>10:00–13:00</b></p> <p><b>14:30–16:00</b></p>	<ol style="list-style-type: none"> <li><b>1. Opening of the meeting</b></li> <li><b>2. Adoption of the agenda and programme of work</b> <ul style="list-style-type: none"> <li>• The Steering Committee will be invited to adopt the agenda and programme of work (documents A/MSM/11/1 and A/MSM/11/2).</li> </ul> </li> <li><b>3. Update by the Secretariat on the activities and budget to implement the workplan of the Member State mechanism</b> <ul style="list-style-type: none"> <li>• The Secretariat will deliver a presentation to be followed by a discussion (document A/MSM/11/3).</li> </ul> </li> <li><b>4. Update on the list of prioritized activities for 2022–2023</b> <ul style="list-style-type: none"> <li>• The Secretariat and activity leads will provide updates on the activities as indicated below (document A/MSM/11/4).               <ol style="list-style-type: none"> <li>(a) Strengthen the capacity of national/regional regulatory authorities for the prevention and detection of, and response to, substandard and falsified medical products</li> <li>(b) Develop, expand and maintain global networks of stakeholders to facilitate cooperation and collaboration</li> <li>(c) Improve Member States’ understanding and uptake of technologies to screen and detect substandard and falsified medical products, and the implementation of national traceability systems</li> <li>(d) Leverage the competencies of relevant stakeholders, including policy-makers, procurers, distributors, practitioners, patients and consumers, and good governance to reduce the burden of substandard and falsified medical products</li> <li>(e) Enhance Member States’ capacity to run effective risk communication campaigns for substandard and falsified medical products</li> <li>(f) Enhance Member States’ capacity to expand awareness, effectiveness, impact and outreach in their work on substandard and falsified medical products</li> </ol> </li> </ul> </li> </ol>

	<p>(g) Identify and develop appropriate strategies to understand and address the distribution or supply of substandard and falsified medical products via the internet</p> <p>(h) Develop strategies for national regulatory authorities to mitigate public health risks posed by the distribution of substandard and falsified medical products through informal markets</p> <p><b>5. WHO's participation in relevant global and regional initiatives</b></p> <ul style="list-style-type: none"><li>• The Secretariat will provide an update on WHO engagement in relevant global and regional initiatives, highlighting the linkages with the Member State mechanism (presentation to be followed by discussion).</li></ul> <p><b>6. Future work of the Member State mechanism</b></p> <ul style="list-style-type: none"><li>• Member States will be invited to consider several aspects related to the future work of the Member State mechanism and reflect on the ideas discussed by the Steering Committee at its recent meeting (document A/MSM/11/5) (presentation to be followed by discussion).</li></ul> <p><b>7. Proposed dates of the twelfth meeting of the Member State mechanism</b></p> <ul style="list-style-type: none"><li>• Member States will decide when the twelfth meeting of the mechanism will take place.</li></ul> <p><b>8. Report of the Member State mechanism</b></p> <ul style="list-style-type: none"><li>• Member States will be invited to adopt the meeting report.</li></ul> <p><b>9. Closure of the meeting</b></p>
--	--

= = =